Current stock page

Catalysts

NAMS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

NAMSNewAmsterdam Pharma Company N.V.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$20.14+$0.17 (+0.85%)

Latest quote

  • Momentum
    22
  • Value
    42
  • Quality
    58
  • Risk resilience
    48
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 17, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 41/100

Momentum 22/100 and sentiment — before the next covered event.

Recent coverage
0 articles

Updated — · Sentiment not scored

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 22/100AIQ Edge 2/10 Relative Laggard
Beat rate
38%
3 of 8 reported periods
Average surprise
-8.2%
Across covered historical reports
Latest result
+70.3%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$0.47-$0.14+70.3%$8.82M$19.16M
Aug 5, 2026—-$0.48-$0.52-7.9%$1.88M$3.7M
May 7, 2026—-$0.46-$0.40+13.0%$1.74M$3.04M
Feb 18, 2026—-$0.43-$0.63-45.1%$2.88M$32K
Nov 5, 2025—-$0.38-$0.61-60.5%$5.31M$348K
Aug 6, 2025—-$0.52-$0.15+71.2%$3.49M$22.43M
May 8, 2025—-$0.45-$0.49-8.9%$1.46M$3.22M
Feb 26, 2025—-$0.48-$0.95-97.9%$1.76M$13.23M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
15
Buy
1
Hold
12-month analyst target
$61.00
+202.88% versus current price
Based on 16 analyst observations. Targets are estimates, not predictions.
Low target
$61.00
+202.88% vs latest price
Average target
$61.00
+202.88% vs latest price
High target
$61.00
+202.88% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 17, 2027

Next known earnings or reporting date.

EPS estimate-$0.44

Current analyst expectation for the upcoming report.

Revenue estimate$13.98M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score22

Where event reaction would show up first.

AIQ score41/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
16
Average target
$61.00
Target upside
202.88%
Target range
$61.00 - $61.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

No recent articles have a scored sentiment label.
Positive
0
Neutral
0
Negative
0

No recent company-specific news is available.

Open full news and sentiment

NAMS Catalysts FAQ

What are the next catalysts for NAMS stock?

NAMS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move NAMS stock?

Upcoming events that could move NAMS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could NAMS's next earnings report affect the stock?

NAMS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive NAMS stock higher?

NAMS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt NAMS stock?

NAMS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.